Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban in pediatric subjects with venous thromboembolism
2014-002606-20Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of apixaban in venous thromboembolism (VTE) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Composite of major and clinically relevant non-major bleeding. Started Mar 2015; status: completed.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2014-002606-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002606-20.